According to the United Health Foundation, the misuse of over-the-counter medications accounts for a reported 178,000 hospitalizations annually. The campaign aims to tackle this problem by reminding consumers
AC Immune is focused on developing innovative Alzheimer’s disease therapies using vaccination or passive immunization with antibodies. Both the active and passive immunotherapy is directed against the beta
MDX-1100 targets IP-10 (also known as CXCL10), a chemokine associated with the pathogenesis of multiple inflammatory diseases, including ulcerative colitis. Preclinical studies demonstrate that antibodies targeting IP-10 neutralize
The FDA notified Vicuron that it expects to complete the priority review of the dalbavancin new drug application (NDA) on or before September 21, 2005, which is a
Patients who had demonstrated resistance to the standard first-line chemotherapies of cisplatin and/or paclitaxel received phenoxodiol as an adjunct to one of the two traditional therapies. Results suggest
The discovery, outlined in an article in the journal Molecular Cancer Therapeutics, could have important implications for using immunotherapy to treat prostate cancer, according to Ayyappan Rajasekaran, a
The new enzymes, named AttSite Recombinases, catalyze the irreversible integration or excision of DNA sequences at specific locations within the genome, with broad applications in functional genomics, transgenics
The study, named EPICK is designed to demonstrate that PhosLo (calcium acetate) is effective and safe in controlling elevated phosphorus levels (hyperphosphatemia) in stage 4 chronic kidney disease
IPL455,903 (or HT-0712) is a phosphodiesterase-4 (PDE4) inhibitor being developed by Helicon compound for the treatment of learning and memory disorders. The initial phase I studies were designed
These in vivo and in vitro findings may help guide the future clinical development of Amplimexon, which recently entered a phase I/II study in combination with gemcitabine (Eli
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.